Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms

Future Microbiology

Volumn 9, Issue 5, 2014, Pages 697-711

  Chowdhary, Anuradha ^a   Sharma, Cheshta ^a   Hagen, Ferry ^b   Meis, Jacques F ^b,c  

^a UNIVERSITY OF DELHI   (India)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

aspergillosis; Aspergillus fumigatus; environment; non cyp51A mutation; resistance mechanism

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CHOLESTEROL; CYP51B PROTEIN; ECHINOCANDIN; HAPE PROTEIN; ISAVUCONAZOLE; ITRACONAZOLE; PROTEIN; PYRROLE; RAVUCONAZOLE; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; CYTOCHROME P-450 CYP51A, ASPERGILLUS; CYTOCHROME P-450 CYP51B, ASPERGILLUS; CYTOCHROME P450; FUNGAL PROTEIN; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLUS; ASPERGILLUS FUMIGATUS; FUNGUS ISOLATION; GENE MUTATION; HUMAN; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ASPERGILLOSIS; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION; PATHOGENICITY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; CHOLESTEROL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MUTATION; TRIAZOLES; VORICONAZOLE;

EID: 84903266687     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.27     Document Type: Review

References (105)

1. Denning D, Pleuvry A, Cole D. Global burden of ABPA in adults with asthma and its complication chronic pulmonary aspergillosis in adults. Med. Mycol. 51(4), 361-370 (2013
2. Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J. Infect. Dis. 186(9), 1297-1306 (2002
3. Maertens J, Theunissen K, Verbeken E et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br. J. Haematol. 126(6), 852-860 (2004
4. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: Outcomes and prognostic factors associated with mortality. Clin. Infect. Dis. 44(4), 531-540 (2007
5. Verweij PE, Mellado E, Melchers WJ. Multiple-Triazole-resistant aspergillosis. N. Engl. J. Med. 356(14), 1481-1483 (2007
6. van der Linden JW, Snelders E, Kampinga GA et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg. Infect. Dis. 17(10), 1846-1854 (2011
7. Howard SJ, Cerar D, Anderson MJ et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15(7), 1068-1076 (2009
8. Arendrup MC, Mavridou E, Mortensen KL et al. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS ONE 5(4), e10080 (2010
9. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple-Triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J. Antimicrob. Chemother. 67(2), 362-366 (2012
10. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob. Agents Chemother. 55(9), 4465-4468 (2011
11. Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints. Drug Resist. Updat. 12(6), 141-147 (2009
12. Espinel-Ingroff A, Fothergill A, Fuller J, Johnson E, Pelaez T, Turnidge J. Wild-Type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob. Agents Chemother. 55(6), 2855-2859 (2011
13. Espinel-Ingroff A, Chowdhary A, Gonzalez GM et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob. Agents Chemother. 57(8), 3823-3828 (2013
14. Howard SJ, Lass-Flörl C, Cuenca-Estrella M, Gomez-Lopez A, Arendrup MC. Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob. Agents Chemother. 57(11), 5426-5431 (2013
15. Pfaller MA, Boyken L, Hollis R et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J. Clin. Microbiol. 49(2), 586-590 (2011
16. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monzon A, Cuenca-Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52(7), 2468-2472 (2008
17. Bueid A, Howard SJ, Moore CB et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65(10), 2116-2118 (2010
18. Baddley JW, Marr KA, Andes DR et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 47(10), 3271-3275 (2009
19. Shi JY, Xu YC, Shi Y et al. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin. Chin. Med. J. 123(19), 2706-2709 (2010
20. Tashiro M, Izumikawa K, Minematsu A et al. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob. Agents Chemother. 56(1), 584-587 (2012
21. van der Linden JW, Snelders E, Arends JP, Daenen SM, Melchers WJ, Verweij PE. Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens. J. Clin. Microbiol. 48(4), 1478-1480(2010
22. Denning DW, Park S, Lass-Florl C et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin. Infect. Dis. 52(9), 1123-1129 (2011
23. Spiess B, Seifarth W, Merker N et al. Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients. Antimicrob. Agents Chemother. 56(7), 3905-3910 (2012
24. Denning DW, Venkateswarlu K, Oakley KL et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41(6), 1364-1368 (1997
25. Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B acquired resistance to itraconazole. Scand. J. Infect. Dis. 29, 509-512 (1997
26. Dannaoui E, Borel E, Monier MF, Piens MA, Picot S, Persat F. Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 47(3), 333-340 (2001
27. Mellado E, Garcia-Effron G, Alcazar-Fuoli L et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51(6), 1897-1904 (2007
28. Lagrou K, De Vleeschouwer J, Meerseman W et al. Triazole resistance among 229 clinical Aspergillus fumigatus isolates. Presented at: 3rd Advances Against Aspergillosis. Miami, FL, USA, 16-19 January 2008
29. Snelders E, van der Lee HA, Kuijpers J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5(11), e219 (2008
30. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: Epidemiology and detection. Med. Mycol. 49(Suppl. 1), S90-S95 (2011
31. Mortensen KL, Jensen RH, Johansen HK et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: A laboratory-based study with focus on Aspergillus fumigatus azole resistance. J. Clin. Microbiol. 49(6), 2243-2251 (2011
32. Morio F, Aubin GG, Danner-Boucher I et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J. Antimicrob. Chemother. 67(8), 1870-1873 (2012
33. Burgel PR, Baixench MT, Amsellem M et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob. Agents Chemother. 56(2), 869-874 (2012
34. Alanio A, Sitterlé E, Liance M et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J. Antimicrob. Chemother. 66(2), 371-374 (2011
35. Bader O, Weig M, Reichard U et al. cyp51A-based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany. Antimicrob. Agents Chemother. 57(8), 3513-3517 (2013
36. Alastruey-Izquierdo A, Mellado E, Peláez T et al. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). Antimicrob. Agents Chemother. 57(7), 3380-3387 (2013
37. Escribano P, Peláez T, Muñoz P, Bouza E, Guinea J. Is azole resistance in Aspergillus fumigatus a problem in Spain?. Antimicrob. Agents Chemother. 57(6), 2815-2820 (2013
38. van der Linden JW, Arendrup MC, Verweij PE. SCARE network Prospective international surveillance of azole resistance in Aspergillus fumigatus: SCARE-Network. Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Abstract M-490. Chicago, IL, USA, 17-20 September 2011
39. Seyedmousavi S, Hashemi SJ, Zibafar E et al. Azole-resistant Aspergillus fumigatus, Iran. Emerg. Infect. Dis. 19(5), 832-834 (2013
40. Snelders E, Huis In 't Veld RA, Rijs AJ, Kema GH, Melchers WJ, Verweij PE. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 75(12), 4053-4057 (2009
41. Mortensen KL, Mellado E, Lass-Flörl C, Rodriguez-Tudela JL, Johansen HK, Arendrup MC. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob. Agents Chemother. 54(11), 4545-4549 (2010
42. Chowdhary A, Kathuria S, Xu J et al. Clonal expansion and emergence of environmental multiple-Triazole-resistant Aspergillus fumigatus strains carrying the TR3 4/L98H mutations in the cyp51A gene in India. PLoS ONE 7(12), e52871 (2012
43. Badali H, Vaezi A, Haghani I et al. Environmental study of azole-resistant Aspergillus fumigatus with TR34/L98H mutations in the cyp51A gene in Iran. Mycoses 56(6), 659-663 (2013
44. van der Linden JW, Camps SM, Kampinga GA et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin. Infect. Dis. 57(4), 513-520 (2013
45. Kuipers S, Bruggemann RJ, de Sevaux RG et al. Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole. Antimicrob. Agents Chemother. 55(7), 3564-3566 (2011
46. Vermeulen E, Maertens J, Schoemans H, Lagrou K. Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012. Euro Surveill. 17(48), pii: 20326 (2012
47. Chowdhary A, Sharma C, Kathuria S, Hagen F, Meis JF. Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. J. Antimicrob. Chemother. J. Antimicrob. Chemother. 69(2), 555-557 (2014
48. Mellado E, Diaz-Guerra, TM, Cuenca-Estrella, M, Rodriguez-Tudela JL. Identification of two different 14-Alpha sterol demethylase related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J. Clin. Microbiol. 39(7), 2431-2438 (2001
49. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Substitutions at methionine 220 in the 14-Alpha-sterol demethylase (cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48(7), 2747-2750 (2004
50. Chen J, Li H, Li R, Bu D, Wan Z. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J. Antimicrob. Chemother. 55(1), 31-37 (2005
51. Hodiamont CJ, Dolman KM, Ten Berge IJ, Melchers WJ, Verweij PE, Pajkrt D. Multiple-Azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-Term oral posaconazole and surgery. Med. Mycol. 47(2), 217-220 (2009
52. Klaassen CH, de Valk HA, Curfs-Breuker IM, Meis JF. Novel mixed-format real-Time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-Triazole resistance among clinical isolates in The Netherlands. J. Antimicrob. Chemother. 65(5), 901-905 (2010
53. Klaassen CH, Gibbons JG, Fedorova ND, Meis JF, Rokas A. Evidence for genetic differentiation and variable recombination rates among Dutch populations of the opportunistic human pathogen Aspergillus fumigatus. Mol. Ecol. 21(1), 57-70 (2012
54. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. A point mutation in the 14-Alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47(3), 1120-1124 (2003
55. da Silva Ferreira ME, Capellaro JL, dos Reis Marques E et al. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob. Agents Chemother. 48(11), 4405-4413 (2004
56. Mann PA, Parmegiani RM, Wei SQ et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14-Alpha-demethylase. Antimicrob. Agents Chemother. 47(2), 577-581 (2003
57. Rath PM, Buchheidt D, Spiess B, Arfanis E, Buer J, Steinmann J. First reported case of azole-resistant Aspergillus fumigatus due to the TR/L98H mutation in Germany. Antimicrob. Agents Chemother. 56(11), 6060-6061 (2012
58. Hamprecht A, Buchheidt D, Vehreschild JJ et al. Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro. Surveill. 17(36), 20262 (2012
59. Albarrag AM, Anderson MJ, Howard SJ et al. Interrogation of related clinical pan-Azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter. Antimicrob. Agents Chemother. 55(11), 5113-5121 (2011
60. Jeurissen A, Cooreman S, Van Kerckhoven W et al. Invasive pulmonary aspergillosis due to a multi-Azole resistant Aspergillus fumigatus. Acta Clin. Belg. 67 (1), 46-48 (2012
61. Howard SJ, Webster I, Moore CB et al. Multi-Azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents. 28 (5), 450-453 (2006
62. Bellete B, Raberin H, Morel J, Flori P, Hafid J, Manhsung RT. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med. Mycol. 48(1), 197-200 (2010
63. Pelaez T, Gijón P, Bunsow E et al. Resistance to voriconazole due to a G448S substitution in Aspergillus fumigatus in a patient with cerebral aspergillosis. J. Clin. Microbiol. 50(7), 2531-2534 (2012
64. Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJ. Azole resistance profile of amino acid changes in Aspergillus fumigatus cyp51A based on protein homology modeling. Antimicrob. Agents Chemother. 54(6), 2425-2430 (2010
65. Odds FC, Brown AJ, Gow NA. Antifungal agents: Mechanisms of action. Trends Microbiol. 11(6), 272-279 (2003
66. Groll AH, Gea-Banacloche JC, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ. Clinical pharmacology of antifungal compounds. Infect. Dis. Clin. North Am. 17(1), 159-191 (2003
67. Mohr J, Johnson M, Cooper T, Lewis JS, Ostrosky-Zeichner L. Current options in antifungal pharmacotherapy. Pharmacotherapy 28(5), 614-645 (2008
68. Vanden Bossche H, Koymans L, Moereels H. P450 inhibitors of use in medical treatment: Focus on mechanisms of action. Pharmacol. Ther. 67(1), 79-100 (1995
69. Warrilow AG, Melo N, Martel CM et al. Expression, purification, and characterization of Aspergillus fumigatus sterol 14-Alpha demethylase (CYP51) isoenzymes A and B. Antimicrob. Agents Chemother. 54(10), 4225-4234 (2010
70. Gollapudy R, Ajmani S, Kulkarni SA. Modeling and interactions of Aspergillus fumigatus lanosterol 14-Alpha demethylase 'A' with azole antifungals. Bioorg. Med. Chem. 12(11), 2937-2950 (2004
71. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-Type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48(2), 568-574 (2004
72. Snelders E, Karawajczyk A, Verhoeven RJ et al. The structure-function relationship of the Aspergillus fumigatuscyp51A L98H conversion by site-directed mutagenesis: The mechanism of L98H azole resistance. Fungal Genet. Biol. 48(11), 1062-1070 (2011
73. Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog. 9(10), e1003633 (2013
74. Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: A growing public health concern. Curr. Opin. Infect. Dis. 26(6), 493-500 (2013
75. Mellado E, Garcia-Effron G, Alcazar-Fuoli L et al. A new resistance mechanism to azole drugs in multiple isolates of Aspergillus fumigatus. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Abstract no. M-1581. Washington, DC, USA, 21-24 September 2005
76. Coleman JJ, Mylonakis E. Efflux in fungi: La pièce de résistance. PLoS Pathog. 5(6), e1000486 (2009
77. Tobin MB, Peery RB, Skatrud PL. Genes encoding multiple drug resistance-like proteins in Aspergillus fumigatus and Aspergillus flavus. Gene 200(1-2), 11-23 (1997). (Pubitemid 27460467
78. Slaven JW, Anderson MJ, Sanglard D et al. Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet. Biol. 36(3), 199-206 (2002
79. Nascimento AM, Goldman GH, Park S et al. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob. Agents Chemother. 47(5), 1719-1726 (2003
80. Rajendran R, Mowat E, McCulloch E et al. Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity. Antimicrob. Agents Chemother. 55(5), 2092-2097 (2011
81. da Silva Ferreira ME, Malavazi I, Savoldi M et al. Transcriptome analysis of Aspergillus fumigatus exposed to voriconazole. Curr. Genet. 50(1), 32-44 (2006
82. Fraczek MG, Bromley M, Buied A et al. The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 68(7), 1486-1496 (2013
83. Cools HJ, Fraaije BA. Are azole fungicides losing ground against Septoria wheat disease?. Resistance mechanisms in Mycosphaerella graminicola. Pest Manag. Sci. 64(7), 681-684 (2008
84. Bueid A, Moore CB, Denning DW, Bowyer P. High-level expression of cyp51B in azole-resistant clinical Aspergillus fumigatus isolates. J. Antimicrob. Chemother. 68(3), 512-514 (2013
85. Xiong Q, Hassan SA, Wilson WK et al. Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 49(2), 518-524 (2005
86. Espenshade PJ. SREBPs: Sterol-regulated transcription factors. J. Cell Sci. 119(Pt 6), 973-976 (2006
87. Espenshade PJ, Hughes AL. Regulation of sterol synthesis in eukaryotes. Annu. Rev. Genet. 41, 401-427 (2007
88. Willger SD, Puttikamonkul S, Kim KH et al. A sterol-regulatory element binding protein is required for cell polarity, hypoxia adaptation, azole drug resistance, and virulence in Aspergillus fumigatus. PLoS Pathog. 4(11), e1000200 (2008
89. Willger SD, Grahl N, Cramer RA Jr. Aspergillus fumigatus metabolism: Clues to mechanisms of in vivo fungal growth and virulence. Med. Mycol. 47(Suppl. 1), S72-S79 (2009
90. Blosser SJ, Cramer RA. SREBP-dependent triazole susceptibility in Aspergillus fumigatus is mediated through direct transcriptional regulation of erg11A (cyp51A). Antimicrob. Agents Chemother. 56(1), 248-257 (2012
91. Blatzer M, Barker BM, Willger SD et al. SREBP coordinates iron and ergosterol homeostasis to mediate triazole drug and hypoxia responses in the human fungal pathogen Aspergillus fumigatus. PLoS Genet. 7(12), e1002374 (2011
92. Camps SM, Dutilh BE, Arendrup MC et al. Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS ONE 7(11), e50034 (2012
93. Verweij PE, Kema GH, Zwaan B, Melchers WJ. Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus. Pest Manag. Sci. 69(2), 165-170 (2013
94. Gisi U. Assessment of selection and resistance risk for DMI fungicides in Aspergillus fumigatus in agriculture and medicine: A critical review. Pest Manag. Sci. 70(3), 352-364 (2013
95. Posteraro B, Posteraro P, Sanguinetti M. Update on antifungal resistance and its clinical impact. Curr. Fungal Infect. Rep. 7, 224-234 (2013
96. Snelders E, Camps SM, Karawajczyk A et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS ONE 7 (3), e31801 (2012
97. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347(6), 408-415 (2002
98. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46(3), 327-360 (2008
99. Steinbach WJ. Are we there yet?. Recent progress in the molecular diagnosis and novel antifungal targeting of Aspergillus fumigatus and invasive aspergillosis. PLoS Pathog. 9(10), e1003642 (2013
100. Marr KA, Schlamm H, Rottinghaus ST et al. A randomized, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. Presented at: 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). London, UK, 31 March-3 April 2012 (Abstract LB2812
101. Seyedmousavi S, Bruggemann RJ, Melchers WJ et al. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. J. Antimicrob. Chemother. 68(2), 385-393 (2013
102. Krishnan-Natesan S, Wu W, Chandrasekar PH. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus. Diagn. Microbiol. Infect. Dis. 73(2), 135-137 (2012
103. van der Linden JW, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med. Mycol. 49(Suppl. 1), S82-S89 (2011
104. Report on economic, financial and market studies to demonstrate the economic value of research carried out by Rothamsted research. www.rothamsted.ac.uk/intopractice/ FungicideResistanceReport.pdf
105. Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species. www.ecdc.europa.eu/en/publications/ Publications/Forms/ECDC-DispForm. aspx?ID=1064.